The pharmaceutical industry has experienced remarkable growth over the last few decades fuelled by sales revenues of blockbuster drugs such as Lipitor® (Pfizer), Plavix® (BMS/Sanofi-Aventis) and Advair® (GlaxoSmithKline). However, as these drugs approach patent expiries, the era of the blockbuster drug can be considered to be coming to an end.

This content is only available as a PDF.